Hematology

Latest News

syringes | Image credit: SOPONE - stock.adobe.com
Analyzing Safety of Switching From Originators to Biosimilars: A Meta-Analysis of 21 Trials

February 10th 2024

The authors of a meta-analysis assessing several disease states found no significant differences in serious adverse events, deaths, or treatment discontinuations between patients who switched from reference products to biosimilars and those who did not.

Blood test | Image Credit: luchschenF - stock.adobe.com
Rituximab Biosimilars Effective in Treating Immune Thrombocytopenia

January 15th 2024

blood stream | Image credit: olegganko - stock.adobe.com
Enoxaparin Biosimilar Shows Similar Efficacy to Originator in Preventing Postoperative Subclinical Thrombosis

December 16th 2023

drug development in lab | Image credit: Nakron - stock.adobe.com
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity

November 29th 2023

blood stream
Phase 1 Study Finds Comparable PK, PD Parameters in Biosimilar GP40141 vs Reference Romiplostim

November 25th 2023

Video Interviews
Podcasts
canadian flag on a mountain
Latest CME Events & Activities

Managed Care Insights on Optimizing the Use of BCMA-Targeted Treatments in Multiple Myeloma

1.5 Credits / Hematology, Oncology

View More

CAR T-Cell Therapy Advances in Lymphoma: Implications for Managed Care

1.5 Credits / Hematology, Oncology

View More

Evidence-Based Oncology: Discerning Novel Approaches, Recent Advances, and the Managed Care Considerations for Targeted Treatments in CLL

2.0 Credits / Hematology, Oncology

View More

Leveraging Managed Care to Increase Access to BCMA-Directed Treatment and Equitable Care in Multiple Myeloma

1.5 Credits / Hematology, Oncology

View More

Leveraging Managed Care to Optimize Patient Outcomes in Acute Myeloid Leukemia

1.5 Credits / Hematology, Oncology

View More

New Pathways in Care for Myelofibrosis: Optimizing Treatment to Improve Outcomes

1.5 Credits / Hematology, Oncology

View More

Managed Care Considerations on the Evolving Role of Bispecific Antibodies in Hematologic Malignancies

1.5 Credits / Hematology, Oncology

View More

Continuing the Conversation in Myelofibrosis: The Role of Managed Care in Supporting Treatment Goals Through Appropriate Use of Emerging Therapies

1.0 Credits / Hematology, Oncology

View More

Supporting Safe, Effective, and Equitable Access to B-Cell Maturation Antigen (BCMA)-Directed Treatments in Multiple Myeloma: Strategies for Specialty and Managed Care Pharmac...

1.5 Credit / Hematology, Oncology

View More

Advances in the Treatment of Myelofibrosis: Updates and Considerations for Managed Care Professionals

1.0 Credit / Hematology, Oncology

View More

More News

© 2024 MJH Life Sciences

All rights reserved.